Ucwaningo olubikwe abacwaningi baseFudan University lubonisa ukuthi inhlanganisela entsha yama-protein biomarker amane angaxilonga ngokunembile umdlavuza pancreatic. (Br J Cancer. Inguqulo ye-inthanethi kaNovemba 9, 2017).
Abacwaningi bathi sikholelwa ukuthi ukuthuthukiswa kwendlela esheshayo futhi ezinzile yokuhlola amaprotheni okuhlosiwe kumasampuli amakhulu kungase kusheshise ijubane lokuthola izimpawu ze-biomarker ezintsha zamaprotheni kanye nokuhlosiwe kwezidakamizwa, futhi kungase kube ngabanye esikhathini esizayo. Ama-proteome asetshenziswa ekwelashweni okunembayo.
Iningi umdlavuza we-pancreatic basesigabeni esiphezulu sesifo ngesikhathi sokuxilongwa, futhi izinga lokusinda eliphakathi ngemva kokuxilongwa lingaphansi kuka-6%. Ukuxilongwa kusenesikhathi kanye nokwelashwa kungase kuthuthukise ukubikezela.
Abacwaningi basebenzise amasu ahlukahlukene we-mass spectrometry ukuhlaziya amasampula e-serum ayi-150 avela ezilawulweni ezinempilo, iziguli ezinezifo ze-pancreatic benign, neziguli ezinomdlavuza we-pancreatic, futhi bakhombe amaprotheni ayi-142 avezwe ngokuhlukile. Ekugcineni, amaprotheni amane afakwe kumaphrofayili awo e-biomarker expression: APOE, ITIH3, APOA1 kanye ne-APOL1.
Ngokuhlaziywa kwendawo engaphansi kwendlela yejika (AUC), ukunemba komaka wephrotheni eyodwa esetshenziswa ukuhlukanisa iziguli ezinomdlavuza we-pancreatic nezilawuli ezinempilo kwakuphakathi kuka-66.9% no-89.6%. Inhlanganisela yezimpawu ezine ingakhuphula ukunemba kuye ku-93.7%. Ukuzwela kwenhlanganisela ye-biomarker yamaprotheni amane ekuxilongweni komdlavuza we-pancreatic kwakungu-85%, futhi ukucaciswa kwakungu-94.1%. Uma i-CA19-9 ifakiwe kule ndlela yokuthola, i-AUC izokwenyuswa ibe ngu-0.99, ngaleso sikhathi ukuzwela kuba ngu-95% kanye nokucaciswa kwawo okungu-94.1%.
Abacwaningi baphinde basebenzisa i-immunohistochemistry ukuze baqinisekise ukuvezwa kwezimaka zamaprotheni ezingenhla kumasampula esimila, baphinde baqinisekise ukwethembeka kwale nhlanganisela entsha ye-biomarker.
Abacwaningi bathi ukusetshenziswa komtholampilo kwalawa ma-biomarker kusesenendlela ende okufanele ihambe. I-FDA yase-US isanda kugunyaza inhlanganisela yomaka bokuhlolwa kwesimila esikhungweni somdlavuza weSikhumbuzo Sloan Kettering esibizwa nge-IMPACT. I-IMPACT ingathola ngokushesha ukuguqulwa kofuzo ku-468 nezinye izinguquko zamangqamuzana ekwakhekeni kwe-tumor genome.
